Integrated BioPharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2022
May 12, 2022 at 02:05 pm EDT
Share
Integrated BioPharma, Inc. reported earnings results for the third quarter and nine months ended March 31, 2022. For the third quarter, the company reported sales was USD 15.63 million compared to USD 17.07 million a year ago. Net income was USD 0.797 million compared to USD 1.24 million a year ago. Basic earnings per share from continuing operations was USD 0.03 compared to USD 0.04 a year ago. Diluted earnings per share from continuing operations was USD 0.03 compared to USD 0.04 a year ago.
For the nine months, sales was USD 42.98 million compared to USD 46.5 million a year ago. Net income was USD 2.34 million compared to USD 3.51 million a year ago. Basic earnings per share from continuing operations was USD 0.08 compared to USD 0.12 a year ago. Diluted earnings per share from continuing operations was USD 0.07 compared to USD 0.11 a year ago.
Integrated Biopharma Inc. is engaged primarily in manufacturing, distributing, marketing and sales of vitamins, nutritional supplements, and herbal products. The Companyâs business segments include Contract Manufacturing operated by Manhattan Drug Company, Inc. (MDC), which manufactures vitamins and nutritional supplements for sale to distributors, multilevel marketers and specialized health-care providers; and Other Nutraceutical Businesses, which includes the operations of AgroLabs, Inc. (AgroLabs), The Vitamin Factory (the Vitamin Factory), IHT Health Products, Inc. (IHT), MDC Warehousing and Distribution, Inc., and Chem International, Inc. AgroLabs distributes healthful nutritional products for sale through mass market, grocery and drug and vitamin retailers under the brands: Peaceful Sleep, and Wheatgrass and other products. IHT is a distributor of fine natural botanicals, including multi-minerals produced under a license agreement. Chem is a distributor of raw materials.